The pharmaceutical company reported robust growth in domestic formulations and insulin franchise performance, while maintaining a strong EBITDA margin of 37 per cent
Source :- Companies Read More
August 27, 2026
Eris Lifesciences Q4 profit jumps three-fold to ₹281.6 cr; shares surge 11%
- No Comments
- 6 Min Read
Share it :
Get free tips and resources right in your inbox, along with 10,000+ others
Categories
Latest Post
